Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryHealth Net Kisunla Coverage Update, Prior Auth | O…
    Ask Trek AI about this page
    ModifiedHealth NetPolicy CP PHAR.594

    Clinical Policy: Donanemab-azbt (Kisunla)

    Customize your policy alerts

    Sign up for Health Net Policy CP PHAR.594 alerts

    Get alerted when Policy CP PHAR.594 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization criteria for donanemab-azbt (Kisunla) in members with mild cognitive impairment due to Alzheimer disease or mild Alzheimer dementia for Health Net lines of business.

    Policy Summary
    PayerHealth Net
    PolicyClinical Policy: Donanemab-azbt (Kisunla)
    Policy CodePolicy CP PHAR.594
    Change TypeMaterial revisions to criteria, exclusions, and authorization durations
    Effective DateJul 2, 2024
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation that initial or continued therapy criteria are met; initial approvals cover the first 3 monthly infusions.
    SourceLink
    POLICY UPDATE CHANGES

    Initial approval criteria updated to require specialist prescriber, amyloid verification, specific baseline cognitive and functional scores, MRI requirements, and exclusions for concomitant anticoagulant/antiplatelet therapy and concurrent anti-amyloid antibodies.

    Initial 3-month authorization duration clarified to cover the first 3 monthly infusions.

    Specialist prescriber requirement was added for initial approval.

    Exclusion against concomitant use with other anti-amyloid monoclonal antibodies was added.

    Exclusion for concomitant use with anticoagulant or antiplatelet therapies was added (aligned with Leqembi policy).

    Initial authorization duration clarified to cover the first 3 monthly infusions (not 4) per FDA labeling.

    Follow-up MRI requirements for continued therapy were added/updated to identify new-onset ARIA.

    Per-approval reauthorization interval for members with >=7 total infusions shortened from 12 infusions to 6 infusions per authorization.

    Requirement for enrollment in an NIH-sponsored trial was removed for both initial and continued therapy.

    Maximum dosing limits and approval durations were added/updated.

    Exclusion against concomitant use with Aduhelm was removed.

    Age limit of 60-85 years was removed.

    Attestation requirement regarding discussion of ApoE4 status with the member was added.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    700→1400Dosing regimen (initial then maintenance)
    1,400 mgMax dose q4w
    3 monthsInitial approval duration
    J0175HCPCS
    6 infusionsPer-approval reauth (≥7 infusions)
    removedNIH trial enrollment

    Coverage Criteria for Donanemab-azbt (Kisunla)

    Initial Therapy

    Covered when ALL of the following are met:

    Initial Approval - Alzheimer's Disease: 1) Diagnosis of mild cognitive impairment (MCI) due to Alzheimer disease or mild Alzheimer dementia (see Appendix E); 2) Prescribed by or in consultation with a geriatrician or neurologist; 3) Documentation of the presence of beta-amyloid plaques verified by PET scan or cerebrospinal fluid testing; 4) Baseline cognitive testing: MMSE score 20-28 OR MoCA score ≥ 16; 5) Baseline functional testing: FAQ score < 9 OR FAST score 3-4 OR CDR-SB 0.5-9; 6) Recent (within the last year) brain MRI demonstrating all of the following: absence of ARIA-E, < 1 area of superficial siderosis, < 4 cerebral microhemorrhages, absence of any macrohemorrhage, and no severe white matter disease; 7) Member is not currently taking concomitant anticoagulant or antiplatelet therapy; 8) Kisunla is not prescribed concurrently with other anti-amyloid monoclonal antibodies (e.g., Leqembi); 9) Prescriber attestation that the prescriber has discussed with the member the potentially increased risk of ARIA in ApoE4 homozygotes; 10) Dose does not exceed 1,400 mg every 4 weeks.all conditions required

    Approval duration: 3 months (first 3 infusions)

    Continuation Therapy

    Continued coverage when ALL of the following are met:

    Continued Therapy - Alzheimer's Disease: 1) Member is currently receiving medication via the benefit or previously met initial approval criteria; 2) Member is responding positively to therapy as evidenced by slowed decline in cognition; 3) Ongoing cognitive and functional testing consistent with mild disease (MMSE 20-28 OR MoCA ≥ 16; FAQ < 9 OR FAST 3-4 OR CDR-SB 0.5-9); 4) Prior to the 4th and 7th infusions, documentation of a recent (within the last month) brain MRI and ARIA symptom assessment demonstrating: absence of symptomatic ARIA-E or only mild symptoms, FLAIR hyperintensity confined to sulcus and/or cortex/subcortex and < 5 cm in any one location, < 4 cerebral microhemorrhages, and absence of macrohemorrhage; 5) Member is not currently taking concomitant anticoagulant or antiplatelet therapy; 6) Kisunla is not prescribed concurrently with other anti-amyloid monoclonal antibodies; 7) Approval durations tied to infusion count: members with < 4 total infusions: up to the 4th infusion; members with 4-6 total infusions: up to the 7th infusion; members with ≥ 7 total infusions: 6 infusions per prior authorization approval.all conditions required

    MRI monitoring required before key infusions

    Initial and Continued Therapy Criteria (summary)

    Covered when ALL of the following are met (high-level summary from document revisions):

    Prescriber and patient-level requirements: Prescribed by a specialist (geriatrician or neurologist); prescriber attestation that ApoE4 status was discussed with the member; not concurrently receiving other anti-amyloid monoclonal antibodies; not on concomitant anticoagulant or antiplatelet therapy; no pre-existing stroke, TIA, or seizures.

    Specialist prescriber and exclusions added in 4Q2023 revisions.

    Initial authorization covers the first 3 monthly infusions per FDA labeling; NIH trial enrollment requirement removed.3 monthly infusions

    Clarified in 07.05.23 and later updates.

    Continued therapy requires follow-up MRI to identify new-onset ARIA and ongoing cognitive/functional testing to confirm the member remains in the mild stage of AD; continued use is subject to maximum dosing limits and periodic reauthorization intervals (6 infusions per approval for members with ≥ 7 total infusions).MRI monitoring and cognitive/functional tests

    Requests for indications that are not FDA‑approved and that are not specifically addressed in this policy are excluded unless coverage is supported through the applicable off‑label use policies or an evidence of coverage document (see referenced off‑label policies CP.CPA.09, HIM.PA.154, CP PMN.53).

    Donanemab-azbt (Kisunla) must not be prescribed concurrently with other anti‑amyloid monoclonal antibodies (for example, Leqembi). Concomitant use with another anti‑amyloid monoclonal antibody is an explicit exclusion for both initiation and continuation of therapy.

    Members who are currently taking anticoagulant or antiplatelet therapy are excluded from initiation and continuation of Kisunla. Concurrent anticoagulant or antiplatelet use is an explicit contraindication to coverage under this policy and must be reconciled prior to approval.

    Donanemab-azbt (Kisunla) is contraindicated in individuals with a history of serious hypersensitivity to donanemab-azbt or to any of its excipients. Known serious hypersensitivity reactions preclude use under this policy.

    Additional exclusions and safety‑related limitations include: no concurrent treatment with other anti‑amyloid monoclonal antibodies; no concurrent anticoagulant or antiplatelet therapy; and exclusion for members with pre‑existing neurologic conditions such as prior stroke, transient ischemic attack (TIA), or seizures as noted in the policy updates. Operational safety requirements include baseline and interval brain MRI monitoring for amyloid‑related imaging abnormalities (ARIA) and adherence to the policy’s maximum dosing limits and infusion‑based reauthorization cadence.

    Use of Kisunla for non‑FDA indications that are not specifically covered by this policy is not supported by this policy and is subject to off‑label adjudication per the referenced off‑label use policies; absent such coverage determinations, those uses are not authorized under this policy.

    Use of Kisunla in patients who meet any of the explicit exclusion criteria listed in this policy (for example, concurrent anti‑amyloid monoclonal antibody therapy, concurrent anticoagulant/antiplatelet therapy, known serious hypersensitivity, or relevant pre‑existing neurologic conditions) is considered not medically necessary and will be denied.

    Coding and Dose Limits

    HCPCS CodesHCPCS
    J0175Injection, donanemab-azbt, 2 mg
    Covered HCPCS CodesHCPCSCovered
    J0175Injection, donanemab-azbt 2 mg
    Dose limits — regimen and maximum
    Initial dosing regimen700 mg IV every 4 weeks for the first 3 doses (initial phase)
    Maintenance dosing regimen1400 mg IV every 4 weeks after the initial 3-dose phase
    Maximum dose per 4 weeks1,400 mg every 4 weeks
    Per-authorization reauth infusions threshold
    >=7 infusions ruleMembers with >= 7 total infusions: per-authorization reauthorization cadence shortened to 6 infusions per prior-authorization (i.e., 6-month reauth intervals)
    Previous cadencePreviously provided 12 infusions per PA for perpetual reauthorization (changed in 4Q2024)

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for initiation of Kisunla. Initial approvals cover the first 3 monthly infusions (approval duration = 3 months / 3 doses). Continued authorization is required for ongoing treatment and is contingent on required MRI monitoring and clinical response criteria.

    • Initial approval duration: 3 months (first 3 monthly infusions).
    • Continued authorization: MRI-contingent reauthorization schedule per criteria; see Continued Therapy for reauthorization windows (up to 4th, up to 7th, then 6 infusions per PA approval for members with ≥7 total infusions).
    • Prior authorization must document specialist prescriber status and all required baseline tests and imaging.
    Denial Risk

    Concomitant Therapy and Medical‑History Exclusions

    Do not prescribe Kisunla concomitantly with other anti‑amyloid monoclonal antibodies or with anticoagulant or antiplatelet therapy. Members with a history of stroke, TIA, or seizures are excluded. Providers must confirm current medications and relevant medical history prior to approval.

    Definitions and Assessment Tools

    ARIA — definitions and safety
    ARIA definitionAmyloid-related imaging abnormalities (ARIA) — radiographic findings on MRI associated with anti-amyloid therapies
    ARIA-EARIA-E: amyloid-related imaging abnormalities — edema (fluid-related signal changes)
    ARIA-HARIA-H: amyloid-related imaging abnormalities — hemosiderin deposition (microhemorrhages/superficial siderosis)
    Boxed warning & monitoringKisunla carries a boxed warning for increased risk of ARIA; monitoring with MRI and ARIA symptom assessment is required per policy
    Dementia scales and eligibility score ranges
    MMSEMini-Mental State Examination (MMSE) score 20–28 used to define eligible mild cognitive impairment/mild AD

    Background

    Donanemab-azbt (Kisunla) is a human monoclonal antibody targeting amyloid beta indicated for treatment of patients with mild cognitive impairment due to Alzheimer disease or mild Alzheimer dementia when prescribed and monitored consistent with the policy criteria. The policy aligns approval criteria with clinical‑trial populations and requires specialist prescriber oversight, amyloid verification, baseline cognitive and functional testing, and MRI monitoring for amyloid‑related imaging abnormalities (ARIA).

    Revision History

    2024-08-07revisedLatest

    Per-approval reauthorization interval for members with >=7 total infusions shortened from 12 infusions to 6 infusions; exclusion against concomitant use with Aduhelm removed; references and HCPCS code updated to J0175.

    2024-07-05clarified

    Initial authorization duration clarified to cover the first 3 monthly infusions (not 4) to align with FDA labeling.

    2023-11-22
    Policy Summary
    PayerHealth Net
    PolicyClinical Policy: Donanemab-azbt (Kisunla)
    Policy CodePolicy CP PHAR.594
    Change TypeMaterial revisions to criteria, exclusions, and authorization durations
    Effective DateJul 2, 2024
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation that initial or continued therapy criteria are met; initial approvals cover the first 3 monthly infusions.
    SourceLink
    On This Page
    Coverage Criteria for Donanemab-azbt (Kisunla)Coding and Dose LimitsProvider Actions, Prior Authorization, and DocumentationDefinitions and Assessment ToolsBackgroundRevision History

    Added/updated in 4Q2023 and 4Q2024 reviews.

    PurposeAligns reauthorization approach with Leqembi (6 months at a time)
    • Prohibited concomitant therapies: other anti‑amyloid monoclonal antibodies (e.g., Leqembi) and anticoagulants/antiplatelets.
    • Medical‑history exclusions: prior stroke, TIA, or seizures.
    • Prescriber attestation: discussion with member about ApoE4‑related ARIA risk required.
    Note

    Formulary / Off‑Label Pathway

    Route requests through the appropriate formulary / off‑label adjudication pathway: follow the line‑of‑business policies for formulary, non‑formulary, and off‑label uses. If the drug is on the formulary/PDL follow the applicable no‑coverage criteria policy; if not on formulary follow the non‑formulary policy; if use is off‑label and not otherwise addressed, route per the off‑label use policy.

    • Formulary on PDL: follow CP.CPA.190 (commercial), HIM.PA.33 (HIM), CP PMN.255 (Medicaid) as applicable.
    • Non‑formulary: follow CP.CPA.190 (commercial), HIM.PA.103 (HIM), CP PMN.16 (Medicaid).
    • Off‑label requests: follow CP.CPA.09 (commercial), HIM.PA.154 (HIM), CPPMN.53 (Medicaid) when the indication is not specifically authorized.
    Step Therapy

    Step Therapy / Sequencing Notes

    Step‑therapy and sequencing rules: Kisunla may not be used concurrently with other anti‑amyloid antibodies and is contraindicated with anticoagulant/antiplatelet concomitant use. Sequencing should ensure Kisunla is not prescribed at the same time as Leqembi or other anti‑amyloid agents; prior exposures should be documented and reviewed before authorization.

    • Exclusion for concomitant anti‑amyloid antibodies (e.g., Leqembi).
    • Exclusion for concomitant anticoagulant or antiplatelet therapy.
    • Document prior biologic exposure and sequencing rationale in the PA submission.
    MoCAMontreal Cognitive Assessment (MoCA) score >=16 used to define eligible mild cognitive impairment/mild AD
    FAQFunctional Assessment Questionnaire (FAQ) score <9 used as an eligibility functional cutoff
    FASTFunctional Assessment Staging Test (FAST) score 3–4 indicates mild dementia and used for eligibility
    CDR-SBClinical Dementia Rating – Sum of Boxes (CDR‑SB) score ~0.5–9 (references indicate 0.5–4 suggests questionable to mild; policy uses 0.5–9 range) used to confirm mild disease
    ARIA — MRI follow-up for continued therapy
    Follow-up MRI requirementFollow-up MRI is required (MRI-contingent monitoring) to identify new-onset ARIA prior to key infusions and for continued therapy
    Timing examplesPolicy requires recent MRI prior to the 4th and 7th infusions and additional MRI monitoring per continued therapy criteria
    PurposeDetects ARIA-E/ARIA-H to guide continuation, dose decisions, and safety monitoring
    ApoE4 discussion attestation
    Attestation requiredPrescriber must attest that ApoE4 status and the potentially increased ARIA risk for ApoE4 homozygotes were discussed with the member prior to initiation
    Who must attestPrescribing specialist (geriatrician or neurologist) or prescriber documenting discussion
    DocumentationAttestation must be included in submitted clinical documentation for prior authorization
    added

    Specialist prescriber requirement, exclusions for concomitant use with other anti-amyloid antibodies and anticoagulant/antiplatelet therapy, ApoE4 discussion attestation, and MRI/cognitive monitoring requirements were added as part of 4Q2023 updates to align criteria with TRAILBLAZER-ALZ 2 and CMS registry requirements.

    2022-10-10created

    Policy created pre-emptively establishing initial clinical criteria, dosing limits, and monitoring expectations for donanemab-azbt (Kisunla).